Orsema SC Injection 0.25 mg/0.188 ml is not intended for use in patients with type 1 diabetes or to treat diabetic ketoacidosis
Ongoing phase 3 trials are studying the medication for: Type 2 diabetes Weight management Osteoarthritis Non-alcoholic fatty liver disease (NAFLD) Obstructive sleep apnea in obese and overweight adults
Every production batch is tested for identity, purity, potency, and sterility before release, ensuring that the product you receive is exactly what is specified on the label
Roos CM, Zhang B, Palmer AK, et al
Not every woman who experiences retrograde menstruation develops endometriosis, which suggests a combination of genetic, environmental, and immunological influences are involved
Combining GLP-1 analogues with other weight loss medications may enhance results, and researchers continue to study their long-term efficacy and sustainability